BioCheck, Inc. has acquired DRG International, a manufacturer of clinical diagnostic and research ELISAs with distributors in over 110 countries.
DRG is also the manufacturer of the DRG:HYBRiD-XL, a fully automated analyzer for immunoassays and clinical chemistry. DRG International, Inc.operates in accordance with the FDA 21 CFR 820 Quality System Regulation as well as the ISO 13485:2016 and MDSAP (Medical Device Single Audit Program) by TÜV Rheinland.
“The DRG:HYBRiD-XL and BioCheck’s new automated chemiluminescent platform (ACL-Platform) will enable us to accelerate the availability of optimized, reliable and accurate advanced clinical and research diagnostic tests in the neurological disorders and other diseases,” says Roy Paxton Yih, CEO of BioCheck, Inc. “Leveraging BioCheck’s assay development capabilities with DRG’s development center, the combined companies are well positioned to rapidly scale availability of current tests and develop novel IVD tests for several diseases in the future globally to over 110 countries. We look forward to welcoming the highly talented members of the DRG team who bring additional R&D capabilities and manufacturing strength to BioCheck, helping to further elevate our clinical and research IVD business.”